ESMO and the Triple Meeting approach.

The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.

Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Genmab acquires the Dutch biotech for $8bn.

BNT329 enters the clinic, as do four other new ADCs.

ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

Four more failed tiragolumab trials, including Imbrave-152, will feature.

The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.